Sumitomo Mitsui Trust Group Inc. cut its stake in Quantum-Si Incorporated (NASDAQ:QSI – Free Report) by 10.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,690,720 shares of the company’s stock after selling 526,779 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Quantum-Si were worth $5,160,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Prudential Financial Inc. purchased a new position in shares of Quantum-Si during the second quarter valued at about $25,000. Capital Investment Advisory Services LLC raised its stake in Quantum-Si by 100.0% in the third quarter. Capital Investment Advisory Services LLC now owns 20,000 shares of the company’s stock worth $28,000 after buying an additional 10,000 shares in the last quarter. Cerity Partners LLC purchased a new stake in Quantum-Si in the second quarter worth about $29,000. Elite Life Management LLC purchased a new stake in Quantum-Si in the third quarter worth about $29,000. Finally, HBK Sorce Advisory LLC bought a new stake in Quantum-Si during the 3rd quarter valued at approximately $30,000. 39.90% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, Director Paula Dowdy purchased 109,890 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were bought at an average price of $0.95 per share, for a total transaction of $104,395.50. Following the purchase, the director directly owned 269,107 shares of the company’s stock, valued at approximately $255,651.65. This represents a 69.02% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Charles R. Kummeth acquired 500,000 shares of Quantum-Si stock in a transaction that occurred on Thursday, March 5th. The shares were bought at an average cost of $0.92 per share, with a total value of $460,000.00. Following the transaction, the director owned 855,000 shares in the company, valued at $786,600. This represents a 140.85% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders sold 54,429 shares of company stock worth $45,708. Insiders own 22.04% of the company’s stock.
Quantum-Si Price Performance
Quantum-Si (NASDAQ:QSI – Get Free Report) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Quantum-Si had a negative net margin of 4,160.06% and a negative return on equity of 43.90%. The business had revenue of $0.45 million for the quarter, compared to analysts’ expectations of $0.76 million. Research analysts expect that Quantum-Si Incorporated will post -0.65 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
QSI has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Quantum-Si in a research report on Friday, March 27th. Canaccord Genuity Group dropped their price target on Quantum-Si from $1.50 to $1.00 and set a “hold” rating on the stock in a research report on Wednesday, March 4th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Quantum-Si has an average rating of “Hold” and a consensus price target of $3.25.
Get Our Latest Analysis on Quantum-Si
About Quantum-Si
Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.
Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.
Further Reading
Want to see what other hedge funds are holding QSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quantum-Si Incorporated (NASDAQ:QSI – Free Report).
Receive News & Ratings for Quantum-Si Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum-Si and related companies with MarketBeat.com's FREE daily email newsletter.
